Proactive Investors - Run By Investors For Investors

Scancell surges after announcing milestone in development of its solid tumours treatment

Scancell has a clinical development partnership with Cancer Research UK, the world's leading cancer charity dedicated to saving lives through research
Cancer article in a newspaper
Scancell's ImmunoBody immunotherapy platform activates the body's immune system

Scancell Holdings PLC (LON:SCLP) and the cancer charity Cancer Research UK have announced further progress with Scancell's SCIB2 cancer immunotherapy vaccine.

Pre-clinical studies have demonstrated that the administration of SCIB2 as a liposomal nanoparticle results in potent immune responses and prolonged survival.

READ Scancell in vanguard of immuno-oncology advances, with two technologies that show early promise

The nanoparticle technology uses known lipid (soluble biomolecules) carriers that are optimised to deliver SCIB2 DNA to immune cells. The liposomal nanoparticles protect the DNA from degradation and facilitate efficient uptake, expression and T-cell activation against cancer cells, said Scancell.

The nanoparticle delivery system provides an alternative approach to electroporation - an electrical technique that involves the application of high-voltage electric pulses in short bursts – that has been used to deliver other ImmunoBody agents to patients.

Cancer Research UK is now planning a clinical trial to investigate the safety and efficacy of the SCIB2-nanoparticle complex in patients with solid tumours.

Dr Cliff Holloway, the chief executive officer of Scancell, said the latest milestone “moves us one step closer to entering the clinic”.

“This new nanoparticle approach to deliver SCIB2 is expected to achieve results that are as effective as, or even better than, electroporation. We believe SCIB2 has the potential to provide a much-needed treatment option for patients suffering from a range of common solid tumours including NSCLC, the most frequent cause of cancer death globally,” Holloway added.

Dr Nigel Blackburn, Cancer Research UK's director of drug development, said the vaccine could bring about urgently needed improvements for some cancer treatments.

“Our collaboration with Scancell, combining extensive expertise and experience in drug development, will help bring this treatment to the patients that need it sooner,” Blackburn declared.

Shares in Scancell were up 12% at 4.75p in early deals.

View full SCLP profile View Profile

Scancell Holdings PLC Timeline

Related Articles

Scientists in a lab
January 31 2019
CEO Gary Phillips says Pharmaxis’ healthy cash balance gives it time to choose between in-house and partnering options.
researcher at microscope
May 24 2019
Its lead asset, RXC004, is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors
scientist in lab
February 25 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use